Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 2
2013 1
2014 1
2018 1
2019 3
2022 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Lixisenatide in Early Parkinson's Disease.
Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O; LIXIPARK Study Group. Meissner WG, et al. Among authors: dellapina e. N Engl J Med. 2024 Apr 4;390(13):1176-1185. doi: 10.1056/NEJMoa2312323. N Engl J Med. 2024. PMID: 38598572 Clinical Trial.
Trial of Deferiprone in Parkinson's Disease.
Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, Růžička E, Dušek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory-Magne F, Walter U, de Bie RMA, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo JP, Pigny P, Garçon G, Simonin O, Carpentier J, Rolland AS, Nyholm D, Scherfler C, Mangin JF, Chupin M, Bordet R, Dexter DT, Fradette C, Spino M, Tricta F, Ayton S, Bush AI, Devedjian JC, Duce JA, Cabantchik I, Defebvre L, Deplanque D, Moreau C; FAIRPARK-II Study Group. Devos D, et al. N Engl J Med. 2022 Dec 1;387(22):2045-2055. doi: 10.1056/NEJMoa2209254. N Engl J Med. 2022. PMID: 36449420 Clinical Trial.
Emerging analgesic drugs for Parkinson's disease.
Perez-Lloret S, Rey MV, Dellapina E, Pellaprat J, Brefel-Courbon C, Rascol O. Perez-Lloret S, et al. Among authors: dellapina e. Expert Opin Emerg Drugs. 2012 Jun;17(2):157-71. doi: 10.1517/14728214.2012.677949. Epub 2012 Apr 25. Expert Opin Emerg Drugs. 2012. PMID: 22530847 Review.
Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.
Corvol JC, Durif F, Meissner WG, Azulay JP, Haddad R, Guimarães-Costa R, Mariani LL, Cormier-Dequaire F, Thalamas C, Galitzky M, Boraud T, Debilly B, Eusebio A, Houot M, Dellapina E, Chaigneau V, Salis A, Lacomblez L, Benel L, Rascol O; French NS-Park/F-CRIN Network. Corvol JC, et al. Among authors: dellapina e. Parkinsonism Relat Disord. 2019 Mar;60:51-56. doi: 10.1016/j.parkreldis.2018.10.005. Epub 2018 Oct 4. Parkinsonism Relat Disord. 2019. PMID: 30297210 Clinical Trial.
Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?
Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, Defebvre L, Defer G, Dellapina E, Doé de Maindreville A, Geny C, Maltête D, Meissner WG, Rascol O, Thobois S, Torny F, Tranchant C, Vidailhet M, Corvol JC, Degos B; NS-Park/F-CRIN Network study group. Mariani LL, et al. Among authors: dellapina e. Parkinsonism Relat Disord. 2019 Jul;64:226-234. doi: 10.1016/j.parkreldis.2019.04.012. Epub 2019 Apr 25. Parkinsonism Relat Disord. 2019. PMID: 31047798
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O; NS-Park CIC Network. Ory-Magne F, et al. Among authors: dellapina e. Neurology. 2014 Jan 28;82(4):300-7. doi: 10.1212/WNL.0000000000000050. Epub 2013 Dec 26. Neurology. 2014. PMID: 24371304 Clinical Trial.